Skip to content
  • Saturday, 12 September 2026
  • 6:40 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • OrsoBio’s LXR Inverse Agonist Shows Promise for Hard-to-Treat Triglyceride Disorders, Paving New Path Beyond GLP-1 Dominance
Laboratory Automation & Robotics

OrsoBio’s LXR Inverse Agonist Shows Promise for Hard-to-Treat Triglyceride Disorders, Paving New Path Beyond GLP-1 Dominance

Lana Keisha Apr 14, 2026 0

OrsoBio, a specialized biotechnology firm dedicated to pioneering therapies for obesity and its associated metabolic conditions, is strategically charting a…

Read More
Laboratory Automation & Robotics

OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders

Lana Keisha Apr 3, 2026 0

OrsoBio, a specialized biotechnology company strategically focused on addressing obesity and its myriad related metabolic dysfunctions, is charting a course…

Read More
Laboratory Automation & Robotics

OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders

Lana Keisha Mar 26, 2026 0

OrsoBio, a specialized biotechnology firm dedicated to pioneering treatments for obesity and its associated metabolic disorders, is strategically charting a…

Read More
Laboratory Automation & Robotics

OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders and pioneering a new frontier in obesity therapeutics

Lana Keisha Mar 19, 2026 0

OrsoBio, a dynamic biotech enterprise dedicated to advancing novel therapies for obesity and a spectrum of obesity-related metabolic disorders, is…

Read More
Higher Midlife Vitamin D Levels Linked to Lower Tau Protein Years Later, Offering New Insight for Neurodegenerative Disease ResearchGenetic Mutations Shared by Cancer and Blood Cells Identified as Potential Drivers of Alzheimer’s Disease PathogenesisThe Ascent of Collaborative AI: Fostering a New Era of Human-Machine SynergyNovartis Secures Dual Regulatory Milestones: European Approval for Rhapsido and WHO Prequalification for Coartem Baby
Japan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetLLMOps in 2026: The 10 Tools Every Team Must Have
A novel immune organ inside the skull directs brain defense and may offer a new way to fight brain cancer and neurodegenerative diseaseThe oral exposure challenge in PROTACs: What drug developers need to solve earlyAttention Unleashed: Rethinking ADHD as a Conduit for Creative Innovation in the Modern Neurological LandscapeHarmonic Shielding: Harvard Researchers Use Microscopic Sound Waves to Protect Fragile Quantum Information
YOU MAY HAVE MISSED
Biotech & Genetic Research
A novel immune organ inside the skull directs brain defense and may offer a new way to fight brain cancer and neurodegenerative disease
Jia Lissa Sep 12, 2026
Laboratory Automation & Robotics
The oral exposure challenge in PROTACs: What drug developers need to solve early
Lana Keisha Sep 12, 2026
Neuroscience & Brain Research
Attention Unleashed: Rethinking ADHD as a Conduit for Creative Innovation in the Modern Neurological Landscape
Rifan Muazin Sep 12, 2026
Advanced Materials Science
Harmonic Shielding: Harvard Researchers Use Microscopic Sound Waves to Protect Fragile Quantum Information
Nila Kartika Wati Sep 12, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ